Vertex Inc. (VERX)
Stocks on the Move: Vertex Pharma, Shake Shack, Zoom, Lennar and Home Depot
The CNBC 'Halftime Report' Investment Committee weighs in on 'Stocks on the Move' and their picks.
Why Is Vertex Pharmaceuticals Stock Trading Lower On Thursday After Back Pain Trial Data?
On Thursday, Vertex Pharmaceuticals Incorporated VRTX announced results from its Phase 2 study of suzetrigine for painful lumbosacral radiculopathy (LSR), a disorder that causes pain in the lower back and hip that radiates down the back of the thigh into the leg.
Vertex Pharmaceuticals Stock Heads for Worst Day in 4 Years
Shares of Vertex Pharmaceuticals Inc (NASDAQ:VRTX) are plummeting today, down 13% at $389.21, after the biotech company's non-opioid painkiller, Suzetrigine, matched the placebo in a phase 2 study.
Vertex Pharmaceuticals Stock Dives After Mixed Drug Study Results
Vertex Pharmaceuticals (VRTX) shares sank Thursday morning after the company reported mixed results in a Phase 2 drug trial to treat lumbosacral radiculopathy (LSR), which causes leg and back pain.
Cramer's Stop Trading: Vertex Pharmaceuticals
CNBC's Jim Cramer explains why he is keeping an eye on shares of Vertex Pharmaceuticals.
Vertex Non-Opioid Drug Doesn't Best Placebo In Back Pain Study. The Stock Is Plunging.
Vertex Pharmaceuticals reported that its non-opioid drug reduced back pain significantly. But Vertex stock plunged as a placebo showed similar results.
Vertex Pharmaceuticals: Progress Check Suggests Stock Remains A Solid Buy
I'm updating my recent “Buy” thesis on Vertex Pharmaceuticals Incorporated — spoiler alert, I am as bullish, if not more so, than I was back in September, despite a recent sell-off. Vertex's CF franchise remains robust, with TRIKAFTA generating $2.77bn in Q3 revenues and the upcoming Vanzacaftor triple therapy expected to drive further growth. Casgevy, a CRISPR-based therapy for Sickle Cell Disease and TDT, shows promising commercial potential, with multi-billion-dollar peak revenue projections and expanding global approvals.
Vertex Has $5 Billion-Plus Opportunity In Pain And Kidney Disease Programs, Analyst Upgrades Stock
Jefferies has upgraded Vertex Pharmaceuticals Inc. VRTX, citing the company's robust cystic fibrosis base business and the additional upside from the new LNP/ mRNA therapy (around $1 billion opportunity) and “triple pill” regimens.
Vertex (VERX) is an Incredible Growth Stock: 3 Reasons Why
Vertex (VERX) could produce exceptional returns because of its solid growth attributes.
Vertex (VERX) is a Great Momentum Stock: Should You Buy?
Does Vertex (VERX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Vertex, Inc. (VERX) Hit a 52 Week High, Can the Run Continue?
Vertex (VERX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Is Vertex Stock Worth Buying Despite Its 105% Year-to-Date Rally?
VERX's impressive financial performance, accelerating cloud transition and strategic positioning make it a strong contender in the tax compliance market.
